Guggenheim Maintains Buy Rating for Rubius Therapeutics, Lowers Price Target To $5

Guggenheim has decided to maintain its Buy rating of Rubius Therapeutics RUBY and lower its price target from $25.00 to $5.00.

Shares of Rubius Therapeutics are trading down 24.14% over the last 24 hours, at $2.42 per share.

A move to $5.00 would account for a 106.61 increase% shift from the current share price.

About Rubius Therapeutics

Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.